Edesa Biotech director granted 19,000 shares

Liu Da David reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Liu Da David reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. reported that director Da David Liu received a grant of 19,000 Common Shares in the form of restricted share units. The award was made at a stated price of $0.00 per share, reflecting equity-based compensation rather than a market purchase.

These restricted share units were granted under the company’s 2019 Equity Incentive Compensation Plan and will vest in equal monthly installments over twelve months starting from the grant date. Following this grant, Liu directly holds 24,501 Common Shares, showing a routine increase in his equity stake tied to compensation.

Insider Trade Summary

Grant/Award: 19,000 shares

Grant/Award 1 txn

Insider Liu Da David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	19,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 24,501 shares (Direct)

Footnotes (1)

1. F1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Key Figures

RSU grant size: 19,000 Common Shares Grant price: $0.00 per share Post-grant holdings: 24,501 Common Shares +1 more

4 metrics

RSU grant size 19,000 Common Shares Restricted share unit grant to director Da David Liu

Grant price $0.00 per share Equity compensation award, not an open-market purchase

Post-grant holdings 24,501 Common Shares Total Common Shares directly held after the transaction

Vesting period 12 months RSUs vest in equal monthly installments from the grant date

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, Common Shares, Grant, award, or other acquisition

4 terms

restricted share units financial

"Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions"

Common Shares financial

"security_title: Common Shares, transaction_shares: 19000.0000"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Edesa Biotech (EDSA) disclose in this Form 4 for Da David Liu?

Edesa Biotech disclosed that director Da David Liu received a grant of 19,000 Common Shares. The shares are in the form of restricted share units that vest monthly over twelve months under the 2019 Equity Incentive Compensation Plan.

How many Edesa Biotech (EDSA) shares did Da David Liu receive and at what price?

Da David Liu was granted 19,000 Common Shares at a stated price of $0.00 per share. This indicates a compensation-related award, not an open-market purchase, and reflects equity incentives granted by the company’s board.

How does this Form 4 change Da David Liu’s holdings in Edesa Biotech (EDSA)?

After the grant, Da David Liu directly holds 24,501 Common Shares of Edesa Biotech. The filing shows his position increased through equity compensation, giving him a larger ownership stake aligned with shareholder interests.

What are the vesting terms of Da David Liu’s restricted share units at Edesa Biotech (EDSA)?

The restricted share units granted to Da David Liu vest in equal proportions over twelve months. Vesting begins on the grant date, meaning a portion of the 19,000 units becomes fully owned each month during the one-year period.

Is Da David Liu’s Form 4 transaction in Edesa Biotech (EDSA) a market buy or a compensation grant?

The Form 4 reports a compensation grant, not a market buy. Code A identifies a grant or award acquisition, and the $0.00 per-share price confirms these 19,000 Common Shares were issued as equity-based compensation rather than purchased in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Da David

(Last) (First) (Middle)

C/O EDESA BIOTECH, INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/27/2026		A		19,000(1)	A	$0(1)	24,501	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

	/s/ Da David Liu	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)